RecruitingNCT06512220
Psilocybin with or without risperidone for treatment-resistant depression
About this title
Read the official source — NCT06512220Medication studyAges 18–65Canada
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 21, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 12
- Sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06512220
- Official title
Show the full official title
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin 25 mg and Risperidone 1 MG.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
